Efficacy and Safety of Dalbavancin As Suppressive Therapy
Recruiting now
Conditions studied: Efficacy and Safety of Dalbavancin, In Subjects Who Received SAT with DAL, For Acute or Chronic Infections Between July 2019 and December 2024
In brief
Dalbavancin (DAL) is a semi-synthetic antibiotic that belongs to the lipoglycopeptide family and is structurally derived from teicoplanin, respect of which it has two structural differences that enhance its anti-staphylococcal binding affinity and extend its half-life to between 149 and 250 hours. It achieves adequate tissue penetration in the skin, bones, joints, lung tissues, and peritoneal space, maintaining concentrations above the MIC for susceptible Gram-positive pathogen. DAL is a bactericidal antimicrobial agent that binds the C-terminal D-alanyl-D-alanine on the bacterial cell wall, blocking trans-glycosylation and transpeptidation processes essential for cell wall synthesis. It seems also to be able to enhance neutrophil antibacterial activity improving PMNs' intracellular killing of MRSA. It has also a good antibiofilm activity, alone or in combination with other molecules. Like other glycopeptide molecules, DAL shares a similar spectrum of activity, with demonstrated in vitro activity against various Gram-positive bacteria, including Staphylococcus spp, Streptococcus spp and Enterococcus (faecium, and faecalis). Resistance to DAL is possible in these gram-positives bacteria, given to presence of enzymes that produce low-affinity binding precursors for the antibiotic's binding site. DAL is capable to overcome Van-B mechanism of resistance, but it results not active in producing Van-A strains. The study objectives was to evaluate efficacy and safety of DAL treatment.
Key facts
- Study ID
- NCT06899906
- Run by
- Hospices Civils de Lyon
- People needed
- 33
- Starts
- 2024-10-01
- Expected to finish
- 2025-05-01
- Last updated by the study team
- 2025-03-28
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- > 18 years
- Patients received SAT with DAL for acute or chronic infections (defined as a long-standing infection due to a previously uneradicated pathogen, following unsuccessful antibiotic or surgical treatments) between July 2019 and December 2024
- Patient who was informed and did not object to participating in the study
You may not qualify if…
- -< 18 years
- Subjects who received DAL not for SAT purposes
Where it is running
- HCL — France, Lyon, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.